Thrombopoiesis-stimulating agents and myelodysplastic syndromes

British Journal of Haematology

Volumn 169, Issue 3, 2015, Pages 309-323

  Brierley, Charlotte K ^a   Steensma, David P ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Eltrombopag; Myelodysplastic syndromes; Romiplostim; Thrombocytopenia; Thrombopoietin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AVATROMBOPAG; AZACITIDINE; CORTICOSTEROID; ELTROMBOPAG; HEMOSTATIC AGENT; IMMUNOGLOBULIN; LENALIDOMIDE; OPRELVEKIN; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIESIS STIMULATING AGENT; THROMBOPOIETIN RECEPTOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; THROMBOPOIETIN;

ALLOIMMUNIZATION; ANEMIA; APOPTOSIS; BONE NECROSIS; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; LEUKOCYTOSIS; LIVER DYSFUNCTION; MORBIDITY; MORTALITY; MUCOSAL BLEEDING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; OVERALL SURVIVAL; PETECHIA; PNEUMONIA; PRESYNCOPE; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTIGO; VOMITING; COMPLICATION; DRUG COMBINATION; METABOLISM; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84927641846     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13285     Document Type: Review

References (118)

1. Albitar, M., Manshouri, T., Kantarjian, H., Keating, M., Estrov, Z., Faber, J., Freireich, E.J., Pierce, S. & Estey, E. (1999) Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leukemia Research, 23, 63-69.
2. Aul, C., Giagounidis, A., Germing, U. & Ganser, A. (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Annals of Hematology, 81, 485-497.
3. Bartley, T.D., Bogenberger, J., Hunt, P., Li, Y.S., Lu, H.S., Martin, F., Chang, M.S., Samal, B., Nichol, J.L., Swift, S., Johnson, M.J., Hsu, R.-Y., Parker, V.P., Suggs, S., Skrine, J.D., Merewether, L.A., Clogston, C., Hsu, E., Hokom, M.M., Hornkohl, A., Choi, E., Pangelinan, M., Sun, Y., Mar, V., McNinch, J., Simonet, V., Jacobsen, F., Xie, C., Shutter, J., Chute, H., Basu, R., Selander, L., Trollinger, D., Sieu, L., Padilla, D., Trail, G., Elliott, G., Izumi, R., Covey, T., Crouse, J., Garcia, A., Xu, W., Del Castillo, J., Biron, J., Cole, S., Hu, M.C.-T., Pacifici, R., Ponting, I., Saris, C., Wen, D., Yung, Y.P., Lin, H. & Rosselman, R.A. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell, 77, 1117-1124.
4. Bauermeister, D.E. (1971) Quantitation of bone marrow reticulin-a normal range. American Journal of Clinical Pathology, 56, 24-31.
5. Berthelot-Richer, M., Boilard, B., Morin, A., Bolduc, B., Beauregard, P. & Kotb, R. (2012) Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. Transfusion, 52, 739-741.
6. Borge, O.J., Ramsfjell, V., Veiby, O.P., Murphy, M.J. Jr, Lok, S. & Jacobsen, S.E. (1996) Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood, 88, 2859-2870.
7. van den Bosch, J., Lubbert, M., Verhoef, G. & Wijermans, P.W. (2004) The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leukemia Research, 28, 785-790.
8. Bourgeois, E., Caulier, M.T., Rose, C., Dupriez, B., Bauters, F. & Fenaux, P. (2001) Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia, 15, 950-953.
9. Bouscary, D., Preudhomme, C., Ribrag, V., Melle, J., Viguie, F., Picard, F., Guesnu, M., Fenaux, P., Gisselbrecht, S. & Dreyfus, F. (1995a) Prognostic value of c-mpl expression in myelodysplastic syndromes. Leukemia, 9, 783-788.
10. Bouscary, D., Prudhomme, C., Quesnel, B., Melle, J., Picard, F. & Dreyfus, F. (1995b) c-mpl expression in hematologic disorders. Leukaemia & Lymphoma, 17, 19-26.
11. Bowles, K.M., Warner, B.A. & Baglin, T.P. (2006) Platelet mass has prognostic value in patients with myelodysplastic syndromes. British Journal of Haematology, 135, 198-200.
12. Broudy, V.C. & Lin, N.L. (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine, 25, 52-60.
13. Bussel, J.B., Cheng, G., Saleh, M.N., Psaila, B., Kovaleva, L., Meddeb, B., Kloczko, J., Hassani, H., Mayer, B., Stone, N.L., Arning, M., Provan, D. & Jenkins, J.M. (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357, 2237-2247.
14. Bussel, J.B., Provan, D., Shamsi, T., Cheng, G., Psaila, B., Kovaleva, L., Salama, A., Jenkins, J.M., Roychowdhury, D., Mayer, B., Stone, N. & Arning, M. (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet, 373, 641-648.
15. Bussel, J.B., Kuter, D.J., Aledort, L.M., Kessler, C.M., Cuker, A., Pendergrass, K.B., Tang, S. & McIntosh, J. (2014) A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 123, 3887-3894.
16. Cheng, G., Saleh, M.N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., Arning, M., Stone, N.L. & Bussel, J.B. (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, 377, 393-402.
17. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
18. Corazza, F., Hermans, C., D'Hondt, S., Ferster, A., Kentos, A., Benoit, Y. & Sariban, E. (2006) Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood, 107, 2525-2530.
19. Cwirla, S.E., Balasubramanian, P., Duffin, D.J., Wagstrom, C.R., Gates, C.M., Singer, S.C., Davis, A.M., Tansik, R.L., Mattheakis, L.C., Boytos, C.M., Schatz, P.J., Baccanari, D.P., Wrighton, N.C., Barrett, R.W. & Dower, W.J. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 276, 1696-1699.
20. D'Arena, G., Guariglia, R., Mansueto, G., Martorelli, M.C., Pietrantuono, G., Villani, O., Lerose, R. & Musto, P. (2013) No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood, 121, 1240-1242.
21. Debili, N., Wendling, F., Cosman, D., Titeux, M., Florindo, C., Dusanter-Fourt, I., Schooley, K., Methia, N., Charon, M. & Nador, R. (1995) The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood, 85, 391-401.
22. Demeter, J., Istenes, I., Fodor, A., Paksi, M., Dombi, P., Valasinyoszki, E., Csomor, J., Matolcsy, A. & Nagy, Z.G. (2011) Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathology Oncology Research, 17, 141-143.
23. Desmond, R.T., Townsley, D., Olnes, M., Scheinberg, P., Dumitriu, B., Parikh, A., Broder, K., Calvo, K., Wu, C., Young, N. & Dunbar, C. (2013) Is it possible to cure severe aplastic anaemia refractory to immunosuppressive therapy without transplant? A long term follow up analysis of a phase II study of eltrombopag. p. S1106. 18th Congress of the European Hematology Association, Stockholm.
24. Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., Tsuboi, K., Nitta, M., Miyazaki, H., Iida, S. & Ueda, R. (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood, 103, 4198-4200.
25. Drachman, J.G., Griffin, J.D. & Kaushansky, K. (1995) The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. Journal of Biological Chemistry, 270, 4979-4982.
26. Erickson-Miller, C.L., Delorme, E., Tian, S.S., Hopson, C.B., Landis, A.J., Valoret, E.I., Sellers, T.S., Rosen, J., Miller, S.G., Luengo, J.I., Duffy, K.J. & Jenkins, J.M. (2009) Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells, 27, 424-430.
27. Feese, M.D., Tamada, T., Kato, Y., Maeda, Y., Hirose, M., Matsukura, Y., Shigematsu, H., Muto, T., Matsumoto, A., Watarai, H., Ogami, K., Tahara, T., Kato, T., Miyazaki, H. & Kuroki, R. (2004) Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proceedings of the National Academy of Sciences of the USA, 101, 1816-1821.
28. Fenaux, P. (1996) Myelodysplastic syndromes. Hematology and Cell Therapy, 38, 363-380.
29. Fenaux, P. & Ades, L. (2013) How we treat lower-risk myelodysplastic syndromes. Blood, 121, 4280-4286.
30. Fenaux, P., Raza, A., Mufti, G.J., Aul, C., Germing, U., Kantarjian, H., Cripe, L., Kerstens, R., De Porre, P. & Kurzrock, R. (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood, 109, 4158-4163.
31. Fontenay-Roupie, M., Dupont, J.M., Picard, F., Fichelson, S., Botella, A., Melle, J., Guesnu, M., Casadevall, N., Dreyfus, F. & Bouscary, D. (1998) Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leukemia Research, 22, 527-535.
32. Garcia-Manero, G., Shan, J., Faderl, S., Cortes, J., Ravandi, F., Borthakur, G., Wierda, W.G., Pierce, S., Estey, E., Liu, J., Huang, X. & Kantarjian, H. (2008) A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 22, 538-543.
33. George, J.N., Mathias, S.D., Go, R.S., Guo, M., Henry, D.H., Lyons, R., Redner, R.L., Rice, L. & Schipperus, M.R. (2009) Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. British Journal of Haematology, 144, 409-415.
34. Giagounidis, A., Mufti, G.J., Fenaux, P., Sekeres, M.A., Szer, J., Platzbecker, U., Kuendgen, A., Gaidano, G., Wiktor-Jedrzejczak, W., Hu, K., Woodard, P., Yang, A.S. & Kantarjian, H.M. (2014) Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer, 120, 1838-1846.
35. Gilli, S.C., de Souza Medina, S., de Castro, V., Fernandes, L.G. & Saad, S.T. (2012) Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes. Leukemia Research, 36, 554-559.
36. Girtovitis, F.I., Ntaios, G., Papadopoulos, A., Ioannidis, G. & Makris, P.E. (2007) Defective platelet aggregation in myelodysplastic syndromes. Acta Haematologica, 118, 117-122.
37. González-Porras, J.R., Cordoba, I., Such, E., Nomdedeu, B., Vallespi, T., Carbonell, F., Luno, E., Ardanaz, M., Ramos, F., Pedro, C., Gomez, V., de Paz, R., Sanchez-Barba, M., Sanz, G.F. & Del Canizo, A.C. (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer, 117, 5529-5537.
38. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
39. Greenberg, P.L., Young, N.S. & Gattermann, N. (2002) Myelodysplastic syndromes. Hematology / the American Society of Hematology Education Program, 1, 136-161.
40. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454-2465.
41. Greenberg, P.L., Garcia-Manero, G., Moore, M., Damon, L., Roboz, G., Hu, K., Yang, A.S. & Franklin, J. (2013) A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukaemia & Lymphoma, 54, 321-328.
42. Heddle, N.M., Cook, R.J., Webert, K.E., Sigouin, C. & Rebulla, P. (2003) Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 43, 742-752.
43. Hellstrom, E., Birgegard, G., Lockner, D., Helmers, C., Ost, A. & Wide, L. (1991) Treatment of myelodysplastic syndromes with recombinant human erythropoietin. European Journal of Haematology, 47, 355-360.
44. Hellstrom-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A. & Greenberg, P. (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344-351.
45. Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Oberg, G., Porwit-MacDonald, A., Radlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. & Wisloff, F. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 1037-1046.
46. Houwerzijl, E.J., Blom, N.R., van der Want, J.J., Vellenga, E. & de Wolf, J.T. (2006) Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia, 20, 1937-1942.
47. Ichikawa, N., Ishida, F., Shimodaira, S., Tahara, T., Kato, T. & Kitano, K. (1996) Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thrombosis and Haemostasis, 76, 156-160.
48. Jenkins, J.M., Williams, D., Deng, Y., Uhl, J., Kitchen, V., Collins, D. & Erickson-Miller, C.L. (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood, 109, 4739-4741.
49. Kalina, U., Hofmann, W.K., Koschmieder, S., Wagner, S., Kauschat, D., Hoelzer, D. & Ottmann, O.G. (2000) Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Experimental Hematology, 28, 1158-1163.
50. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, R. 3rd, Shen, L., Nimer, S.D., Leavitt, R., Raza, A. & Saba, H. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794-1803.
51. Kantarjian, H., Giles, F., List, A., Lyons, R., Sekeres, M.A., Pierce, S., Deuson, R. & Leveque, J. (2007) The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer, 109, 1705-1714.
52. Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J.M., List, A., Fenaux, P., Sanz, G., Issa, J.P., Freireich, E.J. & Garcia-Manero, G. (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 113, 1351-1361.
53. Kantarjian, H., Fenaux, P., Sekeres, M.A., Becker, P.S., Boruchov, A., Bowen, D., Hellstrom-Lindberg, E., Larson, R.A., Lyons, R.M., Muus, P., Shammo, J., Siegel, R., Hu, K., Franklin, J. & Berger, D.P. (2010a) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology, 28, 437-444.
54. Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L. & Berger, D.P. (2010b) Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 116, 3163-3170.
55. Kao, J.M., McMillan, A. & Greenberg, P.L. (2008) International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. American Journal of Hematology, 83, 765-770.
56. Kato, T., Ogami, K., Shimada, Y., Iwamatsu, A., Sohma, Y., Akahori, H., Horie, K., Kokubo, A., Kudo, Y. & Maeda, E. (1995) Purification and characterization of thrombopoietin. Journal of Biochemistry, 118, 229-236.
57. Kaushansky, K. (1998) Thrombopoietin. New England Journal of Medicine, 339, 746-754.
58. Kaushansky, K., Lok, S., Holly, R.D., Broudy, V.C., Lin, N., Bailey, M.C., Forstrom, J.W., Buddle, M.M., Oort, P.J., Hagen, F.S., Roth, G.J., Papayannopoulou, T. & Foster, D.C. (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature, 369, 568-571.
59. Kondo, T., Okabe, M., Sanada, M., Kurosawa, M., Suzuki, S., Kobayashi, M., Hosokawa, M. & Asaka, M. (1998) Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood, 92, 1091-1096.
60. Kuter, D.J. (2007) New thrombopoietic growth factors. Blood, 109, 4607-4616.
61. Kuter, D.J. (2014) Milestones in understanding platelet production: a historical overview. British Journal of Haematology, 165, 248-258.
62. Kuter, D.J. & Begley, C.G. (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood, 100, 3457-3469.
63. Kuter, D.J. & Rosenberg, R.D. (1995) The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood, 85, 2720-2730.
64. Kuter, D.J., Beeler, D.L. & Rosenberg, R.D. (1994) The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proceedings of the National Academy of Sciences of the USA, 91, 11104-11108.
65. Kuter, D.J., Bain, B., Mufti, G., Bagg, A. & Hasserjian, R.P. (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology, 139, 351-362.
66. Kuter, D.J., Bussel, J.B., Lyons, R.M., Pullarkat, V., Gernsheimer, T.B., Senecal, F.M., Aledort, L.M., George, J.N., Kessler, C.M., Sanz, M.A., Liebman, H.A., Slovick, F.T., de Wolf, J.T., Bourgeois, E., Guthrie, T.H. Jr, Newland, A., Wasser, J.S., Hamburg, S.I., Grande, C., Lefrere, F., Lichtin, A.E., Tarantino, M.D., Terebelo, H.R., Viallard, J.F., Cuevas, F.J., Go, R.S., Henry, D.H., Redner, R.L., Rice, L., Schipperus, M.R., Guo, D.M. & Nichol, J.L. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 371, 395-403.
67. Kuter, D.J., Mufti, G.J., Bain, B.J., Hasserjian, R.P., Davis, W. & Rutstein, M. (2009) Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood, 114, 3748-3756.
68. Kuter, D.J., Rummel, M., Boccia, R., Macik, B.G., Pabinger, I., Selleslag, D., Rodeghiero, F., Chong, B.H., Wang, X. & Berger, D.P. (2010) Romiplostim or standard of care in patients with immune thrombocytopenia. New England Journal of Medicine, 363, 1889-1899.
69. Kuter, D.J., Mathias, S.D., Rummel, M., Mandanas, R., Giagounidis, A.A., Wang, X. & Deuson, R.R. (2012) Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. American Journal of Hematology, 87, 558-561.
70. Kuter, D.J., Bussel, J.B., Newland, A., Baker, R.I., Lyons, R.M., Wasser, J., Viallard, J.F., Macik, G., Rummel, M., Nie, K. & Jun, S. (2013) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology, 161, 411-423.
71. Lee, S.T., Jang, J.H., Suh, H.C., Hahn, J.S., Ko, Y.W. & Min, Y.H. (2001) Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. American Journal of Hematology, 68, 237-245.
72. List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R. & Zeldis, J.B. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine, 352, 549-557.
73. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J., Knight, R. & Myelodysplastic Syndrome-003 Study (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456-1465.
74. Matsumoto, A., Tahara, T., Morita, H., Usuki, K., Ohashi, H., Kokubo-Watarai, A., Takahashi, K., Shimizu, E., Tsunakawa, H., Ogami, K., Miyazaki, H., Urabe, A. & Kato, T. (1999) Characterization of native human thrombopoietin in the blood of normal individuals and of patients with haematologic disorders. Thrombosis and Haemostasis, 82, 24-29.
75. Matsumura, I., Kanakura, Y., Kato, T., Ikeda, H., Horikawa, Y., Ishikawa, J., Kitayama, H., Nishiura, T., Tomiyama, Y., Miyazaki, H. & Matsuzawa, Y. (1996) The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood, 88, 3074-3082.
76. Mavroudi, I., Pyrovolaki, K., Pavlaki, K., Kozana, A., Psyllaki, M., Kalpadakis, C., Pontikoglou, C. & Papadaki, H.A. (2011) Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leukemia Research, 35, 323-328.
77. Mittelman, M. & Zeidman, A. (2000) Platelet function in the myelodysplastic syndromes. International Journal of Hematology, 71, 95-98.
78. Montero, A.J., Estrov, Z., Freireich, E.J., Khouri, I.F., Koller, C.A. & Kurzrock, R. (2006) Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leukaemia & Lymphoma, 47, 2049-2054.
79. Murphy, M.F. & Waters, A.H. (1990) Platelet transfusions: the problem of refractoriness. Blood Reviews, 4, 16-24.
80. Neukirchen, J., Blum, S., Kuendgen, A., Strupp, C., Aivado, M., Haas, R., Aul, C., Gattermann, N. & Germing, U. (2009) Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. European Journal of Haematology, 83, 477-482.
81. Nichol, J.L. (1998) Thrombopoietin levels after chemotherapy and in naturally occurring human diseases. Current Opinion in Hematology, 5, 203-208.
82. Oliva, E., Santini, V., Zini, G., Palumbo, G., Poloni, A., Cortelezzi, A., Rodeghiero, F., Voso, M., Molteni, A., Sanpaolo, G., Liberati, A., Morabito, F., Balleari, E., Impera, S., Salvi, F., M.A.A., S., Marino, A., Roda, F., Alati, C., Ronco, F., Di Raimondo, F., Leoni, P., Alimena, G., Fioritoni, G., Latagliata, R. & Nobile, F. (2013) Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: results of a prospective, randomized trial. 18th Congress of the European Hematology Association. Haematologica, 98(Suppl. 1), 456.
83. Olnes, M.J., Scheinberg, P., Calvo, K.R., Desmond, R., Tang, Y., Dumitriu, B., Parikh, A.R., Soto, S., Biancotto, A., Feng, X., Lozier, J., Wu, C.O., Young, N.S. & Dunbar, C.E. (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. New England Journal of Medicine, 367, 11-19.
84. Parameswaran, R., Lunning, M., Mantha, S., Devlin, S., Hamilton, A., Schwartz, G. & Soff, G. (2014) Romiplostim for management of chemotherapy-induced thrombocytopenia. Supportive Care in Cancer, 22, 1217-1222.
85. Peck-Radosavljevic, M., Zacherl, J., Meng, Y.G., Pidlich, J., Lipinski, E., Langle, F., Steininger, R., Muhlbacher, F. & Gangl, A. (1997) Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? Journal of Hepatology, 27, 127-131.
86. Peck-Radosavljevic, M., Wichlas, M., Zacherl, J., Stiegler, G., Stohlawetz, P., Fuchsjager, M., Kreil, A., Metz-Schimmerl, S., Panzer, S., Steininger, R., Muhlbacher, F., Ferenci, P., Pidlich, J. & Gangl, A. (2000) Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood, 95, 795-801.
87. Platzbecker, U., Haase, M., Herbst, R., Hanel, A., Voigtmann, K., Thiede, C.H., Mohr, B., Schleyer, E., Leopold, T., Orth, M., Hanel, M., Ehninger, G. & Bornhauser, M. (2005) Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. British Journal of Haematology, 128, 625-630.
88. Platzbecker, U., Wong, R., Verma, A., Abboud, C., Araujo, S., Chiou, T.J., Feigert, J., Yeh, S.P., Goetze, K., Gorin, N.C., Greenberg, P., Kambhampati, S., Kim, Y.J., Lee, J.H., Lyons, R., Ruggeri, M., Santini, V., Cheng, G., Jang, J.H., Chen, C.Y., Dougherty, S., Mannino, F., Kamel, Y.M., Chan, G., Arning, M., Stone, N. & Giagounidis, A. (2013) Placebo-controlled, randomized, phase I/II trial of the thrombo-poietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myeloid leukemia. 18th Congress of the European Hematology Association. Haematologica, 98(Suppl. 1), 455.
89. Polverelli, N., Palandri, F., Iacobucci, I., Catani, L., Martinelli, G. & Vianelli, N. (2013) Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms. British Journal of Haematology, 161, 142-144.
90. Raza, A., Reeves, J.A., Feldman, E.J., Dewald, G.W., Bennett, J.M., Deeg, H.J., Dreisbach, L., Schiffer, C.A., Stone, R.M., Greenberg, P.L., Curtin, P.T., Klimek, V.M., Shammo, J.M., Thomas, D., Knight, R.D., Schmidt, M., Wride, K., Zeldis, J.B. & List, A.F. (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, 111, 86-93.
91. Rosenfeld, C.S., Zeigler, Z.R., Shadduck, R.K. & Nilsson, B. (1997) Phase II study of roquinimex in myelodysplastic syndrome. American Journal of Clinical Oncology, 20, 189-192.
92. Saleh, M.N., Bussel, J.B., Cheng, G., Meyer, O., Bailey, C.K., Arning, M. & Brainsky, A. (2013) Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 121, 537-545.
93. Sanz, G.F., Sanz, M.A. & Greenberg, P.L. (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica, 83, 358-368.
94. Sarpatwari, A., Bennett, D., Logie, J.W., Shukla, A., Beach, K.J., Newland, A.C., Sanderson, S. & Provan, D. (2010) Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica, 95, 1167-1175.
95. de Sauvage, F.J., Hass, P.E., Spencer, S.D., Malloy, B.E., Gurney, A.L., Spencer, S.A., Darbonne, W.C., Henzel, W.J., Wong, S.C., Kuang, W.J., Oles, K.J., Hultgren, B., Solberg, L.A., Goeddel, D.V. & Eaton, D.L. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature, 369, 533-538.
96. Schlemper, R.J., van der Maas, A.P. & Eikenboom, J.C. (1994) Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Annals of Hematology, 68, 153-158.
97. Sekeres, M.A., Kantarjian, H., Fenaux, P., Becker, P., Boruchov, A., Guerci-Bresler, A., Hu, K., Franklin, J., Wang, Y.M. & Berger, D. (2011) Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer, 117, 992-1000.
98. Sekeres, M.A., Giagounidis, A., Kantarjian, H., Mufti, G.J., Fenaux, P., Jia, C., Yang, A.S. & Platzbecker, U. (2014) Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. British Journal of Haematology, 167, 337-345.
99. Shimodaira, S., Ishida, F., Ichikawa, N., Tahara, T., Kato, T., Kodaira, H., Ito, T., Tanaka, E., Sodeyama, T., Kiyosawa, K. & Kitano, K. (1996) Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thrombosis and Haemostasis, 76, 545-548.
100. Silverman, L.R., Holland, J.F., Weinberg, R.S., Alter, B.P., Davis, R.B., Ellison, R.R., Demakos, E.P., Cornell, C.J. Jr, Carey, R.W. & Schiffer, C. (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia, 7(Suppl. 1), 21-29.
101. Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology, 20, 2429-2440.
102. Sohma, Y., Akahori, H., Seki, N., Hori, T., Ogami, K., Kato, T., Shimada, Y., Kawamura, K. & Miyazaki, H. (1994) Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Letters, 353, 57-61.
103. Souyri, M., Vigon, I., Penciolelli, J.F., Heard, J.M., Tambourin, P. & Wendling, F. (1990) A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell, 63, 1137-1147.
104. Sungaran, R., Markovic, B. & Chong, B.H. (1997) Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood, 89, 101-107.
105. Svensson, T., Chowdhury, O., Garelius, H., Lorenz, F., Saft, L., Jacobsen, S.E., Hellstrom-Lindberg, E. & Cherif, H. (2014) A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. European Journal of Haematology, 93, 439-445.
106. Tamura, H., Ogata, K., Luo, S., Nakamura, K., Yokose, N., Dan, K., Tohyama, K., Yoshida, Y., Hamaguchi, H., Sakamaki, H., Kuwaki, T., Tahara, T., Kato, T. & Nomura, T. (1998) Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. British Journal of Haematology, 103, 778-784.
107. Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der Walt, J. & Orazi, A. (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 90, 1128-1132.
108. Thon, J.N. & Italiano, J.E. (2010) Platelet formation. Seminars in Hematology, 47, 220-226.
109. Tsimberidou, A.M., Giles, F.J., Khouri, I., Bueso-Ramos, C., Pilat, S., Thomas, D.A., Cortes, J. & Kurzrock, R. (2005) Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 16, 139-145.
110. Urabe, A., Komatsu, N., Okomoto, T., Yoshida, T., Nakao, S., Nagasawa, T., Yonemura, Y., Takeshita, A., Ikeda, Y., Sawada, K., Hotta, T., Kanamaru, A., Bessho, M., Minami, N., Okamura, T., Jinnai, I., Dan, K., Kankura, Y., Mizoguchi, H. & for the Japanese KRN9000 Study Group (2001) Effects of pegylated recombinant human megakaryocyte growth and development factor on haematopoiesis in patients with aplastic anemia and myelodysplastic syndrome. Experimental Hematology, 29, Abstract 440.
111. Wang, B., Nichol, J.L. & Sullivan, J.T. (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology and Therapeutics, 76, 628-638.
112. Wang, E.S., Lyons, R.M., Larson, R.A., Gandhi, S., Liu, D., Matei, C., Scott, B., Hu, K. & Yang, A.S. (2012) A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology Oncology, 5, 71.
113. Wattel, E., Cambier, N., Caulier, M.T., Sautiere, D., Bauters, F. & Fenaux, P. (1994) Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. British Journal of Haematology, 87, 205-208.
114. Will, B., Kawahara, M., Luciano, J.P., Bruns, I., Parekh, S., Erickson-Miller, C.L., Aivado, M.A., Verma, A. & Steidl, U. (2009) Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood, 114, 3899-3908.
115. Yan, X.Q., Lacey, D., Fletcher, F., Hartley, C., McElroy, P., Sun, Y., Xia, M., Mu, S., Saris, C., Hill, D., Hawley, R.G. & McNiece, I.K. (1995) Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood, 86, 4025-4033.
116. Yang, C., Li, Y.C. & Kuter, D.J. (1999) The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. British Journal of Haematology, 105, 478-485.
117. Zelcer, S. & Bussel, J.B. (2003) Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series. Journal of Thrombosis and Haemostasis, 1(Suppl. 1), P1169.
118. Zimrin, A. & Chumsri, S. (2013) Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim. Annals of Hematology, 92, 1145-1146.